Abstract
ABSTRACT This narrative review provides a comprehensive summary of research findings up to 2023 regarding the impact of vasopressors and vasodilators on medullary oxygenation during cardiopulmonary bypass and septic shock. It encompasses a thorough evaluation of all current vasopressors and vasodilators. Among vasodilators, levosimendan demonstrates superior efficacy, particularly in cases of heart failure following cardiac surgery. In the context of hypotension during such procedures, vasopressin emerges as the most effective vasopressor. In cases of hypotensive septic shock, both vasopressin and angiotensin II appear to be superior in preserving medullary oxygenation. However, it is imperative to emphasize the need for more robust data and randomized controlled human trials to validate these initial findings. Currently, it would be premature to offer definitive clinical recommendations on this matter.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
